Kiniksa Pharmaceuticals (KNSA)
(Real Time Quote from BATS)
$19.35 USD
+0.08 (0.42%)
Updated May 23, 2024 11:27 AM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Price, Consensus and EPS Surprise
KNSA 19.35 +0.08(0.42%)
Will KNSA be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for KNSA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for KNSA
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates
Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why
KNSA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Does Kiniksa Pharmaceuticals, Ltd. (KNSA) Have the Potential to Rally 32.45% as Wall Street Analysts Expect?
Puma Biotechnology (PBYI) Q4 Earnings & Revenues Lag Estimates
Are You Looking for a Top Momentum Pick? Why Kiniksa Pharmaceuticals, Ltd. (KNSA) is a Great Choice
Other News for KNSA
Market Underestimates Kiniksa Pharmaceuticals’ Abiprubart Potential Despite Positive Industry Indicators
Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference
Kiniksa initiated with bullish view at Wells Fargo, here's why
Kiniksa Pharmaceuticals (NASDAQ:KNSA): New Drug Treatment Could Have Upside Potential
Kiniksa Pharmaceuticals Faces Capital Raising Hurdles Amid Stricter UK Shareholder Voting Laws